2024

Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)

Lee, M. M.Y. , Kondo, T., Campbell, R. T., Petrie, M. C. , Sattar, N. , Solomon, S. D., Vaduganathan, M., Jhund, P. S. and McMurray, J. J.V. (2024) Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomised controlled trials. European Heart Journal: Cardiovascular Pharmacotherapy, 10(1), pp. 68-80. (doi: 10.1093/ehjcvp/pvad067) (PMID:37740450) (PMCID:PMC10766905)

Monzo, L. et al. (2024) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2023.11.020) (Early Online Publication)

2023

Kondo, T. et al. (2023) Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16(12), e010898. (doi: 10.1161/CIRCHEARTFAILURE.123.010898) (PMID:37886880)

Matsumoto, S. et al. (2023) Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25(12), pp. 2202-2214. (doi: 10.1002/ejhf.3044) (PMID:37771260)

Butt, J. H. et al. (2023) Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER. European Journal of Heart Failure, 25(11), pp. 2078-2090. (doi: 10.1002/ejhf.3000) (PMID:37634087)

Kondo, T. et al. (2023) Use of win statistics to analyze outcomes in the DAPA-HF and DELIVER trials. NEJM Evidence, 2(11), (doi: 10.1056/EVIDoa2300042)

Kondo, T. et al. (2023) Efficacy of dapagliflozin according to geographic location of patients with heart failure. Journal of the American College of Cardiology, 82(10), pp. 1014-1026. (doi: 10.1016/j.jacc.2023.05.056) (PMID:37610398)

Matsumoto, S., Kondo, T., Jhund, P. S. , Campbell, R. T., Swedberg, K., van Veldhuisen, D. J., Pocock, S. J., Pitt, B., Zannad, F. and McMurray, J. J.V. (2023) Underutilization of mineralocorticoid antagonists in patients with heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 82(11), pp. 1080-1091. (doi: 10.1016/j.jacc.2023.06.021) (PMID:37642608)

Kondo, T. et al. (2023) Clinical characteristics and outcomes in patients with heart failure: are there thresholds and inflection points in left ventricular ejection fraction and thresholds justifying a clinical classification? Circulation, 148(9), pp. 732-749. (doi: 10.1161/CIRCULATIONAHA.122.063642) (PMID:37366061)

Yang, M. et al. (2023) Stroke in patients with heart failure and reduced or preserved ejection fraction. European Heart Journal, 44(31), pp. 2998-3013. (doi: 10.1093/eurheartj/ehad338) (PMID:37358785) (PMCID:PMC10424882)

Yang, M. et al. (2023) Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2962) (PMID:37401511) (Early Online Publication)

Araki, T. et al. (2023) Relationship between the volume of cases and in-hospital mortality in patients with cardiogenic shock receiving short-term mechanical circulatory support. American Heart Journal, 261, pp. 109-123. (doi: 10.1016/j.ahj.2023.03.017) (PMID:37031832)

Kondo, T. et al. (2023) Predicting stroke in heart failure and preserved ejection fraction without atrial fibrillation. Circulation: Heart Failure, 16(7), e010377. (doi: 10.1161/CIRCHEARTFAILURE.122.010377) (PMID:37350280)

Yang, M. et al. (2023) Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2944) (PMID:37369637) (Early Online Publication)

Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)

Tolomeo, P. et al. (2023) Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. European Heart Journal, 44(24), pp. 2202-2212. (doi: 10.1093/eurheartj/ehad210) (PMID:37051752)

Kondo, T., Adachi, T., Koba, K., Okumura, T., Izawa, H., Murohara, T., McMurray, J. J.V. and Yamada, S. (2023) Physical frailty and use of guideline-recommended drugs in patients with heart failure and reduced ejection fraction. Journal of the American Heart Association, 12(12), e026844. (doi: 10.1161/JAHA.122.026844) (PMID:37301739) (PMCID:PMC10356033)

Chatur, S. et al. (2023) Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.2912) (PMID:37210608) (Early Online Publication)

Kondo, T. et al. (2023) Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial. Circulation, 147(14), pp. 1067-1078. (doi: 10.1161/CIRCULATIONAHA.122.062918) (PMID:36876483)

Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)

Kondo, T. et al. (2023) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, 3(1), pp. 122-134. (doi: 10.1016/j.jacasi.2022.10.004) (PMID:36873766) (PMCID:PMC9982290)

2022

Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)

Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, 43(42), pp. 4469-4479. (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (PMCID:PMC9637422)

Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), pp. 4406-4417. (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (PMCID:PMC9622300)

Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, 80(18), pp. 1705-1717. (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668)

Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)

Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, 24(10), pp. 1869-1878. (doi: 10.1002/ejhf.2607) (PMID:35796209)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)

Kondo, T., Jhund, P. S. and McMurray, J. J.V. (2022) Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose? European Journal of Heart Failure, 24(3), pp. 421-430. (doi: 10.1002/ejhf.2447) (PMID:35119172)

Kondo, T. and McMurray, J. J.V. (2022) Re-emergence of heart failure with a normal ejection fraction? European Heart Journal, 43(5), pp. 427-429. (doi: 10.1093/eurheartj/ehab828) (PMID:34878520)

Articles

Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)

Lee, M. M.Y. , Kondo, T., Campbell, R. T., Petrie, M. C. , Sattar, N. , Solomon, S. D., Vaduganathan, M., Jhund, P. S. and McMurray, J. J.V. (2024) Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomised controlled trials. European Heart Journal: Cardiovascular Pharmacotherapy, 10(1), pp. 68-80. (doi: 10.1093/ehjcvp/pvad067) (PMID:37740450) (PMCID:PMC10766905)

Monzo, L. et al. (2024) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2023.11.020) (Early Online Publication)

Kondo, T. et al. (2023) Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16(12), e010898. (doi: 10.1161/CIRCHEARTFAILURE.123.010898) (PMID:37886880)

Matsumoto, S. et al. (2023) Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25(12), pp. 2202-2214. (doi: 10.1002/ejhf.3044) (PMID:37771260)

Butt, J. H. et al. (2023) Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER. European Journal of Heart Failure, 25(11), pp. 2078-2090. (doi: 10.1002/ejhf.3000) (PMID:37634087)

Kondo, T. et al. (2023) Use of win statistics to analyze outcomes in the DAPA-HF and DELIVER trials. NEJM Evidence, 2(11), (doi: 10.1056/EVIDoa2300042)

Kondo, T. et al. (2023) Efficacy of dapagliflozin according to geographic location of patients with heart failure. Journal of the American College of Cardiology, 82(10), pp. 1014-1026. (doi: 10.1016/j.jacc.2023.05.056) (PMID:37610398)

Matsumoto, S., Kondo, T., Jhund, P. S. , Campbell, R. T., Swedberg, K., van Veldhuisen, D. J., Pocock, S. J., Pitt, B., Zannad, F. and McMurray, J. J.V. (2023) Underutilization of mineralocorticoid antagonists in patients with heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 82(11), pp. 1080-1091. (doi: 10.1016/j.jacc.2023.06.021) (PMID:37642608)

Kondo, T. et al. (2023) Clinical characteristics and outcomes in patients with heart failure: are there thresholds and inflection points in left ventricular ejection fraction and thresholds justifying a clinical classification? Circulation, 148(9), pp. 732-749. (doi: 10.1161/CIRCULATIONAHA.122.063642) (PMID:37366061)

Yang, M. et al. (2023) Stroke in patients with heart failure and reduced or preserved ejection fraction. European Heart Journal, 44(31), pp. 2998-3013. (doi: 10.1093/eurheartj/ehad338) (PMID:37358785) (PMCID:PMC10424882)

Yang, M. et al. (2023) Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2962) (PMID:37401511) (Early Online Publication)

Araki, T. et al. (2023) Relationship between the volume of cases and in-hospital mortality in patients with cardiogenic shock receiving short-term mechanical circulatory support. American Heart Journal, 261, pp. 109-123. (doi: 10.1016/j.ahj.2023.03.017) (PMID:37031832)

Kondo, T. et al. (2023) Predicting stroke in heart failure and preserved ejection fraction without atrial fibrillation. Circulation: Heart Failure, 16(7), e010377. (doi: 10.1161/CIRCHEARTFAILURE.122.010377) (PMID:37350280)

Yang, M. et al. (2023) Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2944) (PMID:37369637) (Early Online Publication)

Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)

Tolomeo, P. et al. (2023) Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. European Heart Journal, 44(24), pp. 2202-2212. (doi: 10.1093/eurheartj/ehad210) (PMID:37051752)

Kondo, T., Adachi, T., Koba, K., Okumura, T., Izawa, H., Murohara, T., McMurray, J. J.V. and Yamada, S. (2023) Physical frailty and use of guideline-recommended drugs in patients with heart failure and reduced ejection fraction. Journal of the American Heart Association, 12(12), e026844. (doi: 10.1161/JAHA.122.026844) (PMID:37301739) (PMCID:PMC10356033)

Chatur, S. et al. (2023) Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.2912) (PMID:37210608) (Early Online Publication)

Kondo, T. et al. (2023) Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial. Circulation, 147(14), pp. 1067-1078. (doi: 10.1161/CIRCULATIONAHA.122.062918) (PMID:36876483)

Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)

Kondo, T. et al. (2023) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, 3(1), pp. 122-134. (doi: 10.1016/j.jacasi.2022.10.004) (PMID:36873766) (PMCID:PMC9982290)

Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)

Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, 43(42), pp. 4469-4479. (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (PMCID:PMC9637422)

Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), pp. 4406-4417. (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (PMCID:PMC9622300)

Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, 80(18), pp. 1705-1717. (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668)

Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)

Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, 24(10), pp. 1869-1878. (doi: 10.1002/ejhf.2607) (PMID:35796209)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)

Kondo, T., Jhund, P. S. and McMurray, J. J.V. (2022) Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose? European Journal of Heart Failure, 24(3), pp. 421-430. (doi: 10.1002/ejhf.2447) (PMID:35119172)

Kondo, T. and McMurray, J. J.V. (2022) Re-emergence of heart failure with a normal ejection fraction? European Heart Journal, 43(5), pp. 427-429. (doi: 10.1093/eurheartj/ehab828) (PMID:34878520)